LDL apheresis

Atherosclerosis

Volumn 167, Issue 1, 2003, Pages 1-13

  Thompson, Gilbert R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Coronary angiographic trials; DALI; Dextran sulphate adsorption; Familial hypercholesterolaemia; HELP; Immunoadsorption; Lp(a); Plasma exchange

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; DEXTRAN SULFATE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYACRYLIC ACID; STEROID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACID PRECIPITATION; ANGIOPLASTY; APHERESIS; BLOOD CELL; CELL SEPARATION; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOTE; HUMAN; IMMUNOADSORPTION; INTERMETHOD COMPARISON; LOW DENSITY LIPOPROTEIN APHERESIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; REVIEW; STROKE;

CHOLESTEROL, LDL; CLINICAL TRIALS; DEXTRAN SULFATE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; IMMUNOSORBENT TECHNIQUES; MALE; PLASMAPHERESIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0037371166     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00251-4     Document Type: Review

References (106)

1. Thompson G.R., Lowenthal R., Myant R. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1:1975;1208-1211.
2. Thompson G.R., Myant N.B., Kilpatrick D., Oakley C.M., Raphael M.J., Steiner R.E. Assessment of long-term plasma exchange for familial hypercholesterolaemia. Br. Heart J. 43:1980;680-688.
3. Thompson G.R., Miller J.P., Breslow J.L. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br. Med. J. 291:1985;1671-1673.
4. Lupien P.-J., Moorjani S., Awad J. A new approach to the management of familial hypercholesterolaemia: removal of plasma cholesterol based on the principle of affinity chromatography. Lancet. 1:1976;1261-1265.
5. Stoffel W., Borberg H., Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet. 2:1981;1005-1007.
6. Yokoyama S., Hayashi R., Satani M., Yamamoto A. Selective removal of low density lipoprotein by plasma pheresis in familial hypercholesterolemia. Arteriosclerosis. 5:1985;613-622.
7. Mabuchi H., Michishita I., Takeda M., et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis. 68:1989;19-26.
8. Eisenhauer T., Armstrong V.W., Wieland H., Fuchs C., Scheler F., Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH; first clinical application of the HELP system. Klin. Woch. 65:1987;161-168.
9. Bosch T., Schmidt B., Kleophas W., Otto V., Samtleben W. LDL hemoperfusion - a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis in patients. Artif. Organs. 21:1997;1060-1065.
10. Norda R., Stegmayr B.G. Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish apheresis study group. Transfus. Apheresis. Sci. 24:2001;49-55.
11. Richter W.O., Jacob B.G., Ritter M.M., Sühler K., Vierneisel K., Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism. 42:1993;888-894.
12. Jovin I.S., Taborski U., Muller-Berghaus G. Analysis of the long-term efficacy and selectivity of immunoadsorption columns for low density lipoprotein apheresis. ASAIO J. 46:2000;298-300.
13. Yokoyama S., Hayashi R., Kikkawa T., et al. Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterisation and experimental use in hypercholesterolemic rabbits. Arteriosclerosis. 4:1984;276-282.
14. Gordon B.R., Kelsey S.F., Bilheimer D.W., et al. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am. J. Cardiol. 70:1992;1010-1016.
15. Gordon B.R., Kelsey S.F., Dau P.C., et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am. J. Cardiol. 81:1998;407-411.
16. Maher V.M.G., Kitano Y., Neuwirth C., Gallagher J.J., Thompson G.R., Myant N.B. Effective reduction of plasma LDL levels by LDL apheresis in familial defective apolipoprotein B-100. Atherosclerosis. 95:1992;231-234.
17. Armstrong V.W., Windisch M., Wieland H., et al. Selective continuous extracorporeal elimination of low-density lipoproteins with heparin at acidic pH. Trans. Am. Soc. Artif. Intern. Organs. 29:1983;323-328.
18. Armstrong V.W., Schuff-Werner P., Eisenhauer T., Helmhold M., Stix M., Seidel D. Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels. Chem. Phys. Lipids. 67-68:1994;315-321.
19. Lane D., McConathy W.J., Laughlin L.O., et al. Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy. Atherosclerosis. 114:1995;203-211.
20. Schettler V., Monazahian M., Wieland E., et al. Reduction of hepatitic C virus load by H.E.L.P.-LDL apheresis. Eur. J. Clin. Invest. 31:2001;154-155.
21. Moriarty P.M., Gibson C.A., Shih J., Matias M.S. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis. 158:2001;495-498.
22. Bosch T., Schmidt B., Blumenstein M., Gurland H.J. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif. Organs. 17:1993;640-652.
23. Bosch T., Schmidt B., Kleophas W., et al. LDL hemoperfusion - a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. Artif. Organs. 21:1997;977-982.
24. Drager L.J., Julius U., Kraenzle K., et al. DALI - the first human whole-blood low-density lipoprotein and lipoprotein(a) apheresis system in clinical use: procedure and clinical results. Eur. J. Clin. Invest. 28:1998;994-1002.
25. Jansen M., Banyai S., Schmaldienst S., et al. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia. Wien. Klin. Wochenschr. 112:2000;61-69.
26. Martins K., Ahrenholz P., Matic G.B., et al. Particle release in extracorporeal low-density lipoprotein lowering therapies. Artif. Organs. 24:2000;526-532.
27. Knisel W., Pfohl M., Muller M., et al. Comparative long-term experience with immunoadsorption and dextran sulfate cellulose adsorption for extracorporeal elimination of low-density lipoproteins. Clin. Invest. 72:1994;660-668.
28. Schaumann D., Welch-Wichary M., Voss A., Schmidt H., Olbricht C.J. Prospective cross-over comparisons of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia. Eur. J. Clin. Invest. 26:1996;1033-1038.
29. Richter W.O., Donner M.G., Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther. Apher. 3:1999;203-208.
30. Schmaldienst S., Banyai S., Stulnig T.M., et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis. 151:2000;493-499.
31. Parhofer K.G., Geiss H.C., Schwandt P. Efficacy of different low-density lipoprotein apheresis methods. Ther. Apher. 4:2000;382-385.
32. Bambauer R., Schiefl R., Latza R. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies. Ther. Apher. 4:2000;213-217.
33. Olbricht C.J., Schaumann D., Fischer D. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors. Lancet. 340:1992;908.
34. Koga N., Nagano T., Sato T., Kagasawa K. Anaphylactoid reactions and bradykinin generation in patients treated with LDL-apheresis and an ACE inhibitor. ASAIO J. 39:1993;M288-M291.
35. Sinzinger H., Bednar J., Granegger S., Blazek I., Peskar B.A. LDL-apheresis and concomitant ACE-inhibitor therapy. Atherosclerosis. 105:1994;115-116.
36. Kojima S., Shiba M., Kuramochi M., Yamamoto A. Effect of nafamostat mesilate on bradykinin generation and hemodynamics during LDL apheresis. Artif. Organs. 19:1995;135-139.
37. Bosch T., Lennertz A., Schmidt B., et al. DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood. Artif. Organs. 24:2000;81-90.
38. Pfohl M., Naoumova R.P., Klass C., et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res. 35:1994;1946-1955.
39. Pfohl M., Naoumova R.P., Neuwirth C., et al. Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect. Atherosclerosis. 135:1997;257-262.
40. Kroon A.A., van't Hof M.A., Demacker P.N., Stalenhoef A.F. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 152:2000;519-526.
41. Armstrong V.W., Schleef J., Thiery J., et al. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur. J. Clin. Invest. 19:1989;235-240.
42. Koizumi J., Koizumi I., Uno Y., et al. Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis. 100:1993;65-74.
43. Knisel W., Besenthal I., Muller M., Di Nicuolo A., Risler T., Eggstein M. Effective reduction of elevated lipoprotein(a) serum concentrations by long-term LDL immunoapheresis. Nutr. Metab. Cardiovasc. Dis. 2:1992;106-110.
44. Pokrovsky S.N., Sussekov A.V., Afanasieva O.I., Adamova I.Y., Lyakishev A.A., Kukharchuk V.V. Extracorporeal immunoadsorption for the specific removal of lipoprotein(a) (Lp(a) apheresis): preliminary clinical data. Chem. Phys. Lipids. 67/68:1994;323-330.
45. Thompson G.R., Sussekov A. Radical therapy of atherosclerosis by apheresis or liver transplantation. Woodford F.P., Davignon J., Sniderman A. Atherosclerosis X. 1995;549-552 Elsevier Science BV.
46. Ulrich H., Lackner K.J., Schmitz G. Lipoprotein(a) apheresis in severe coronary heart disease: an immunoadsorption method. Artif. Organs. 22:1998;135-139.
47. Parhofer K.G., Barrett P.H., Demant T., Schwandt P. Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B. J. Lipid Res. 41:2000;1596-1603.
48. Parhofer K.G., Barrett P.H., Demant T., Richter W.O., Schwandt P. Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia. J. Lipid Res. 37:1996;2383-2393.
49. Marais A.D., Naoumova R.P., Firth J.C., Penny C., Neuwirth C.K., Thompson G.R. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. 38:1997;2071-2078.
50. Assogba U., Lepage S., Bruckert E., et al. Blood antioxidants (vitamin E and beta-carotene) in long-term low density lipoprotein apheresis. Clin. Chim. Acta. 235:1995;147-157.
51. Persson-Moschos M., Bonnefont-Rousselot D., Assogba U., et al. Preferential depletion of selenoprotein P in hypercholesterolaemic patients treated by LDL-apheresis. Clin. Chim. Acta. 204:1995;209-212.
52. Leitinger N., Pirich C., Blazek I., Endler G., Sinzinger H. Decreased susceptibility of low-density lipoproteins to in vitro oxidation after dextran-sulfate LDL-apheresis treatment. Atherosclerosis. 126:1996;305-312.
53. Napoli C., Ambrosio G., Scarpato N., et al. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am. Heart J. 133:1997;585-595.
54. Lepage S., Bonnefont-Rousselot D., Bruckert E., et al. Antioxidant status of hypercholesterolemic patients treated with LDL apheresis. Cardiovasc. Drugs Ther. 10:1996;567-571.
55. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
56. Kizaki Y., Ueki Y., Yoshida K., et al. Does the production of nitric oxide contribute to the early improvement after a single low-density lipoprotein apheresis in patients with peripheral arterial obstructive disease? Blood Coagul. Fibrinolysis. 10:1999;341-349.
57. Rubba P., Faccenda F., Di Soma S., et al. Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia. Stroke. 24:1993;1154-1161.
58. Rubba P., Iannuzzi A., Postiglione A., et al. Hemodynamic changes in the peripheral ciruclation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation. 81:1990;610-616.
59. Aengevaeren W.R.M., Kroon A.A., Stalenhoef A.F.H., Uijen G.J.H., Van der Werf T. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. JACC. 28:1996;1696-1704.
60. Knisel W., Di Nicuolo A., Pfohl M., et al. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems. J. Int. Med. 234:1993;479-487.
61. Julius U., Siegert G., Gromeier S. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. Int. J. Artif. Organs. 23:2000;199-206.
62. Schuff-Werner P., Schutz E., Seyde W.C., et al. Improve haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). Eur. J. Clin. Invest. 19:1989;30-37.
63. Richter W.O., Jacob B.G., Ritter M.M., Sühler K., Vierneisel K., Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism. 42:1993;888-894.
64. Walzl M., Lechner H., Walzl B., Schied G. Improved neurological recovery of cerebral infarctions after plasmapheretic reduction of lipids and fibrinogen. Stroke. 24:1993;1447-1451.
65. Walzl B., Walzl M., Valetitsch H., Lechner H. Increased cerebral perfusion following reduction of fibrinogen and lipid fractions. Haemostasis. 25:1995;137-143.
66. Uauy R., Zwiener R.J., Phillips M.J., Petruska M.L., Bilheimer D.W. Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis. J. Pediatr. 120:1992;892-898.
67. Zwiener R.J., Uauy R., Petruska M.L., Huet B.A. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia. J. Pediatr. 126:1995;728-735.
68. Thiery J., Seidel D. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia. Transfus. Sci. 14:1993;249-259.
69. Gordon B.R., Saal S.D. Immunoadsorption and dextran sulfate cellulose LDL-apheresis for severe hypercholesterolemia: the Rogosin Institute experience 1982-1992. Transfus. Sci. 14:1993;261-268.
70. Kitano Y., Thompson G.R. Role of LDL apheresis in the management of hypercholesterolemia. Transfus. Sci. 14:1993;269-280.
71. Lasuncion M.A., Teruel J.L., Alvarez J.J., et al. Changes in lipoprotein(a), LDL-cholesterol and apolipoprotein B in homozygous familial hypercholesterolaemic patients treated with dextran sulfate LDL-apheresis. Eur. J. Clin. Invest. 23:1993;819-826.
72. Stefanutti C., Vivenzio A., Colombo C., et al. Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL-apheresis. Int. J. Artif. Organs. 18:1995;103-110.
73. Thompson G.R. Low-density lipoprotein apheresis and liver transplantation in the management of familial hypercholesterolaemia in childhood. Neil A., Rees A., Taylor C. Hyperlipidaemia in childhood. 1996;67-75 Royal College of Physicians of London. On behalf of The British Hyperlipidaemia Association.
74. Kroon A.A., Swinkels D.W., van Dongen P.W., Stalenhoef A.F. Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis. Metabolism. 43:1994;1164-1170.
75. Teruel J.L., Lasuncion M.A., Navarro J.F., Carrero P., Ortuno J. Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. Metabolism. 44:1995;929-933.
76. Tatami R., Inoue N., Itoh H., et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. LARS Investigators. Atherosclerosis. 95:1992;1-13.
77. Kitabatake A., Sato H., Hori M., et al. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1 year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group. Clin. Ther. 16:1994;416-428.
78. Waidner T., Franzen D., Voelker W., et al. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. Clin. Invest. 72:1994;858-863.
79. Schuff-Werner P., Gohlke H., Bartmann U. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur. J. Clin. Invest. 24:1994;724-732.
80. Thompson G.R., Maher V.M., Matthews S., et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 345:1995;811-816.
81. Kroon A.A., Aengevaeren W.R., van der Werf T., et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclrosis. Circulation. 93:1996;1826-1835.
82. Richter W.O., Donner M.G., Hofling B., Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism. 47:1998;863-868.
83. Nishimura S., Sekiguchi M., Kano T., et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis. 144:1999;409-417.
84. Thompson G.R. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis. 131:1997;1-5.
85. Brensike J.F., Levy R.I., Kelsey S.F., et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 69:1984;313-324.
86. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 264:1990;3007-3012.
87. Mabuchi H., Koizumi J., Shimizu M., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol. 82:1998;1489-1495.
88. Park J.W., Merz M., Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J. Heart Lung Transplant. 16:1997;290-297.
89. Kroon A.A., van Asten W.N., Stalenhoef A.F. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann. Intern. Med. 125:1996;945-954.
90. Koga N., Watanabe K., Kurashige Y., Sato T., Hiroki T. Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. J. Intern. Med. 246:1999;35-43.
91. Daida H., Lee Y.J., Yokoi H., et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial I (L-ART) Group. Am. J. Cardiol. 73:1994;1037-1040.
92. Adachi H., Niwa A., Shinoda T. Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis. Artif. Organs. 19:1995;1243-1247.
93. Yamashita K., Tasaki H., Tsuda Y., Himeno E., Nakashima Y. Can aggressive lipid lowering using low-density lipoprotein apheresis prevent restenosis after percutaneous transluminal coronary angioplasty in patients with normocholesterolemia? Ther. Apher. 2:1998;210-217.
94. Kanemitsu S., Takekoshi N., Matsui S., et al. Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA? Ther. Apher. 2:1998;65-70.
95. Stenvinkel P., Alvestrand A., Angelin B., Eriksson M. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Eur. J. Clin. Invest. 30:2000;866-870.
96. Muso E., Mune M., Fujii Y., et al. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Kidney Int. Suppl. 71:1999;S122-S125.
97. Sakurai M., Muso E., Matushima H., Ono T., Sasayama S. Rapid normalization of interleukin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome. Kidney Int. Suppl. 71:1999;S210-S212.
98. Yokoyama K., Sakai S., Sigematsu T., et al. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin. Nephrol. 50:1998;1-7.
99. Nakao T., Yoshino M., Matsumoto H., et al. Low-density lipoprotein apheresis retards the progression of hyperlipidemic overt diabetic nephropathy. Kidney Int. Suppl. 71:1999;S206-S209.
100. Yukawa S., Mune M., Yamada Y., Otani H., Kishino M., Tone Y. Ongoing clinical trials of lipid reduction therapy in patients with renal disease. Kidney Int. Suppl. 71:1999;S141-S143.
101. Kajinami K., Mabuchi H. Therapeutic effects of LDL apheresis in the prevention of atherosclerosis. Curr. Opin. Lipidol. 10:1999;401-406.
102. Bosch T. Lipid apheresis: from a heroic treatment to routine clinical practice. Artif. Organs. 20:1996;414-419.
103. Maher V.M.G., Thompson G.R. LDL apheresis: role in the treatment of atherosclerosis. J. Irish Coll. Phys. Surgeons. 25:1996;96-99.
104. Vella A., Pineda A.A., O'Brien T. Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia. Mayo Clin. Proc. 76:2001;1039-1046.
105. Moriarty P.M., Gibson C.A. Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses. Curr. Atheroscler. Rep. 3:2001;156-162.
106. Gordon B.R., Stein E., Jones P., Illingworth D.R. Indications for low-density lipoprotein apheresis. Am. J. Cardiol. 74:1994;1109-1112.